Natera (NASDAQ:NTRA) Collaborates with CytoDyn on ctDNA-Guided mCRC Clinical Trials

Natera Inc. (NASDAQ:NTRA) has entered a strategic collaboration with CytoDyn to use its Signatera MRD assay in evaluating clinical trial samples for CytoDyn's CLOVER Phase 2 study of leronlimab, targeting metastatic colorectal cancer patients. The partnership aims to leverage Natera’s oncology database and molecular insights to improve future biomarker-driven patient selection and treatment strategies.

By Maham Fatima Wed, June 17, 2026 at 4:45 PM GMT+3 2 min read · Yahoo Finance · June 17, 2026, 13:45 UTC

Tickers: $NTRA

Topics: Biotechnology Cancer Research Clinical Trials

Read the full article at Yahoo Finance

More World news

Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Pelagos Insurance Capital Reports Mixed Q3 2026 Results with Revenue Beat and EPS Miss Seeking Alpha · November 12, 2026, 18:01 UTC
Aline Accounting Partners Secures $206 Million in Financing Led by Square Nine Capital PR Newswire · November 12, 2026, 18:00 UTC
Egan-Jones November 2026 Report Shows Soft CLO Issuance Amid Improving Credit Metrics PR Newswire · November 12, 2026, 18:00 UTC
Blackbaud Reports Third Quarter Revenue Growth and Strategic AI Integration Motley Fool · November 12, 2026, 17:53 UTC
Sprott Physical Copper Trust Reports Significant Increase in Q3 Net Income Seeking Alpha · November 12, 2026, 17:51 UTC